Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
ABSAR, acid, adipose, Agamree, agonist, Amatsi, Andrade, android, antiviral, apelin, aspect, assimilated, Belgian, benefical, BeNeLux, Bieth, BioAge, BioAlliance, Bioprojet, Boehringer, bon, break, Bruce, BSAR, capsule, carboxykinase, cassation, cast, Catholic, cent, checklist, Chiara, Cit, classed, clawback, cleanically, cMA, CMC, coinsurance, complemented, condemned, consensually, Copenhagen, correponding, creator, curb, cybersecurity, cybersecutity, DC, deeper, Delpharm, departure, deployed, detriment, die, discontinued, diversification, DPS, dramatically, drastic, Edouard, EDP, elucidated, EM, empowered, enriched, enterprise, Estoril, EWGSOP, fatty, Fellmann, firewall, flotation, Foucault, gaitspeed, geopolitical, glucose, grace, Harmony, highlighted, HOMA, huge, hundred, hypertension, hypocaloric, hypolipidemic, IDD, impasse, implicit, Inflation, influenza, Ingelheim, instability, insulin, interestingly, intestinal, intimately, Intracellular, Intsel, Ipsen, IRIIG, ISIN, Jastreboff, Kalupahana, leaseback, lesser, Leuven, lipase, lipoprotein, liraglutide, liver, Lyon, macroeconomic, MasR, Mastoor, MDA, meaningfully, Menarini, missing, Mnemo, modernization, Negam, Nemera, OBA, Olivera, oncology, Onxeo, outburst, PharmD, phosphoenolpyruvate, Pisa, player, pool, Portugal, potent, prednisolone, prednisone, problem, Pulmonology, quick, Quinolia, rationale, replicated, reply, reshaping, residual, revalued, rush, Ruvembri, ScolaRock, securitization, Seghieri, semaglutide, Serova, Servier, shelf, shutdown, Skyepharma, Skypharma, stood, subtracting, summoned, suppression, synergism, synergistic, talk, theoretical, Thoracic, timepoint, tirzepatide, today, top, transduction, tripled, twelve, UCB, unchanged, unsatisfied, unsupported, untitle, untitled, upregulating, urbanization, Valerio, Veru, whichever, White, wholly, window, WL, WLM, Xiang, Yang
Removed:
acceptability, Alternext, analytical, answered, antagonist, argument, bamlanivimab, borrower, Bracknor, Cambridge, circulation, civilian, conflicting, consolidate, constructive, deconsolidated, deficit, derecognized, detached, determinable, dexamethasone, direction, distinguished, diverse, easily, EIR, encouraged, escrow, exact, feasible, Fisher, handed, headcount, hope, house, IC, idebenone, inquiry, interviewed, investee, involvement, judged, judgement, juvenile, Kingdom, LIBOR, lodged, lowest, match, medium, MHRA, notified, opened, ordering, Parel, participated, Patheon, pattern, persistence, postpone, rapporteur, registry, resume, reversed, sarcob, scaled, scaling, segment, SIC, solid, spent, stake, stopped, strike, subjected, supplying, susceptible, tangible, task, Thermo, ticker, undertook, unlicensed, vigorously, web
Filing tables
Filing exhibits
BPTSY similar filings
Filing view
External links
Exhibit 15.1
| KPMG S.A. Tour EQHO 2 Avenue Gambetta CS 60055 92066 Paris la Défense Cedex France | Téléphone : | +33 (0)1 55 68 68 68 |
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the registration statement No. 333-273718 on Form F-1 and the registration statement No. 333-271385 on Form F-3 of our report dated April 8th, 2024, with respect to the consolidated financial statements of Biophytis S.A. and subsidiaries.
KPMG S.A.
Cédric Adens
Partner
Paris, la Défense, France
April 8th, 2024